# US 2022/0031615 A1 · Vesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031615 A1
- Document ID: US20220031615A1
- Status: Published application
- Kind: A1
- Application number: 17/181,796
- Filed: 2021-02-22
- Published: 2022-02-03
- Earliest claimed: 2013-07-31
- Applicants: Sequessome Technology Holdings Limited
- Inventors: Richard Wolf Garraway; William Henry
- Web page: https://patentgrep.com/patent/US20220031615A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 8/14: Liposomes; Vesicles
- A61K 8/39: Derivatives containing from 2 to 10 oxyalkylene groups
- A61K 8/553: {Phospholipids, e.g. lecithin}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/664: Amides of phosphorus acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61Q 19/00: Preparations for care of the skin
- A61K 2800/10: General cosmetic use
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to vesicular formulations for use in the topical administration of a therapeutic, metabolic, cosmetic or structural Agent Of Interest (“AOI”) and methods of administering an AOI.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A vesicle comprising a phospholipid component, a non-ionic surfactant component and a modified component comprising at least one Agent of Interest (AOI), wherein the modified component is a lipid tethered to the AOI or a surfactant tethered to the AOI, or both; and the AOI is tethered such that, when the AOI is on the external surface of the vesicle, a majority of the AOI is external to the vesicular membrane; and the vesicle is deformable to facilitate topical administration of the AOI through the skin of a patient.

### Claim 20 (depends on 19)

The vesicle according to claim 19, wherein the modified component is the surfactant tethered to the AOI.

### Claim 21 (depends on 19)

The vesicle according to claim 19, wherein the modified component is the lipid tethered to the AOI.

### Claim 22 (depends on 19)

The vesicle according to claim 19, wherein the modified component is both the lipid and the surfactant tethered to the AOI.

### Claim 23 (depends on 19)

The vesicle according to claim 19, wherein the vesicle comprises a single AOI.

### Claim 24 (depends on 19)

The vesicle according to claim 19, wherein the vesicle comprises a plurality of AOIs.

### Claim 25 (depends on 24)

The vesicle according to claim 24, wherein the AOIs are homogeneous.

### Claim 26 (depends on 24)

The vesicle according to claim 24, wherein the AOIs are heterogeneous.

### Claim 27 (depends on 19)

The vesicle according to claim 19, wherein the AOI is selected from the group consisting of an element, an ion, an inorganic salt, a small molecule, an amino acid, a peptide, a protein, a micronutrient, a macromolecule, a macrocyclic molecule and combinations thereof.

### Claim 28 (depends on 19)

The vesicle according to claim 19, wherein the AOI is selected from the group consisting of a skin structural protein, a therapeutic protein, a carbohydrate, a chromophore-containing macromolecule, a vitamin, a metal, a metal salt, a non-metallic element, a non-metallic salt, melanin, a melanin analogue, an anti-inflammatory and combinations thereof.

### Claim 29 (depends on 28)

The vesicle according to claim 28, wherein the AOI is selected from the group consisting of a vitamin, a metal, a metal salt and combinations thereof.

### Claim 30 (depends on 28)

The vesicle according to claim 28, wherein the AOI is a NSAID selected from the group consisting of diclofenac, naproxen and combinations thereof.

### Claim 31 (depends on 19)

The vesicle of claim 19, wherein the phospholipid component is phosphatidyl choline, the non-ionic surfactant component is polysorbate 80, and the AOI is selected from the group consisting of ascorbic acid and tripeptide-1.

### Claim 32 (depends on 19)

The vesicle of claim 19, wherein the AOI of the modified component is tethered to the lipid of the modified component via at least one lipid glycerol hydroxyl group of the lipid of the modified component by an ester bond.

### Claim 33 (depends on 19)

The vesicle of claim 19, wherein the AOI of the modified component is tethered to the lipid of the modified component by replacement of a lipid phosphatidyl moiety of the lipid of the modified component with the AOI such that the lipid of the modified component has two fatty acid chains together with the tethered AOI.

### Claim 34 (depends on 19)

The vesicle of claim 19, wherein the AOI is tethered via an ester bond or an amide bond.

### Claim 35 (depends on 19)

The vesicle of claim 19, wherein the AOI is tethered via a polymer chain.

### Claim 36 (depends on 35)

The vesicle of claim 35, wherein the polymer chain is a polyethylene glycol polymer.

### Claim 37 (depends on 19)

A vesicular formulation comprising a plurality of vesicles according to claim 19 and a pharmaceutically acceptable carrier.

### Claim 38 (depends on 37)

A method of delivering an AOI through the skin of a patient, the method comprising topically applying to the skin of the patient the vesicular formulation of claim 37 in an amount sufficient to penetrate the skin to deliver the AOI.
